secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001390478-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Q1 net loss $5.8M; cash $28.4M; reports positive OS in Phase 2 SLS009 AML trial
--------------------------------------------------------------------------------

- Net loss of $5.8M ($0.07 per share) for Q1 2025 vs $9.6M ($0.21) in Q1 2024.
- Cash and cash equivalents $28.4M as of March 31, 2025; plus $4.0M from warrant exercises in April 2025.
- Phase 2 SLS009 in r/r AML: mOS 8.9 mo (AML-MRC) and 8.8 mo (venetoclax-resistant), beating historic 2.5 mo.
- Phase 3 REGAL (GPS) interim analysis supports continuation; final analysis expected 2025.
- Closed $25M registered direct offering in Jan 2025; net proceeds for working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/0001390478-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/sls-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001390478-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer